Drug Profile
GSK 1059615
Alternative Names: GSK 615; GSK1059615Latest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antineoplastics; Small molecules; Thiazolidinediones
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Nov 2009 Pharmacodynamics (mechanism of action) data from a preclinical trial in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
- 12 Aug 2008 Phase-I clinical trials in Cancer in USA (PO)
- 18 Jun 2008 Preclinical trials in Cancer in USA (PO)